Dr Piotr Witkowski said:Another objective I have is to minimize, and eventually eliminate, the need for toxic anti-rejection
medications for transplant protection (to induce immunologic tolerance THE HOLY GRAIL
of transplantation).
To meet this goal, I am preparing a novel cellular therapy based on ex-vivo expanded
Triregulatory Cells (Tregs). We have already optimized Treg production in our Clinical
Laboratory. This therapy can not only benefit transplant patients, but also those with
autoimmune disorders like Type 1 Diabetes.
Currently, we are also conducting several different clinical trials, testing novel approaches
to improve outcomes in Kidney & Pancreatic islet transplantation.
As SVA shareholders is it possible for us to know how he is progressing with this novel cellular
therapy ?
JUNE 15, 2020 SVA completes acquisition of Cellular Local Immune Protection
Technology. We need to know at AGM just what SVA has done with this technology for the past 12 months
a) Have they been testing this coating with mice? If so, for how long, what are the
results? Have they tested with other animals?
b) Have they been working on this subject with Dr W?
c) Have SVA sat on their fannies for the last 12 months and done nothing with this new technology?
We need answers.